LYRM9

Across TCGA pan-cancer cohorts, LYRM9 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated LYRM9 data layer compared with 2 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher LYRM9 RNA is associated with better overall survival. In most high-consensus cancer types, elevated LYRM9 expression acts as an unfavorable survival marker, although some lineages such as MESO and KIRP show a favorable association.

MESO, KIRP, and LUAD are the cancer types where LYRM9 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.688	0.393	<.001	107	view →
KIRP	DFS	Tertile	All	1.000	0.547	<.001	75	view →
LUAD	OS	Median	All	0.865	0.756	<.001	51	view →
ACC	OS	Quartile	All	1.000	0.749	.001	38	view →
LAML	DFS	Median	All	0.396	0.707	.001	36	view →
KIRC	OS	Quartile	All	0.764	0.559	<.001	32	view →
CESC	DFS	Tertile	IV	0.714	0.253	.004	30	view →
PAAD	DFS	Quartile	All	0.469	0.177	.001	26	view →
SARC	DFS	Median	All	0.696	0.523	<.001	22	view →
UCS	DFS	Tertile	All	0.602	0.278	.028	16	view →
SKCM	OS	Tertile	II,III,IV	0.507	0.319	.008	16	view →
PRAD	DFS	Median	All	0.912	0.952	.008	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

LYRM9–MESO (OS)

Open the MESO breakdown →